By 2022 global biosimilar market will cross USD 60 billion mark. India has 20 per cent of world's population but it produces just one per cent of world's biologics. By 2022, Indian bio-pharmaceutical space will go up to US$ 5 billion from existing less than US$1 billion. To capitalize on growing biosimilar ...
Read more: Epygen Biotech eying Indian biosimilar market with 5 drugs under pipeline